Share Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

GlobeNewsWire · IMMP · November 18, 2026

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: GlobeNewsWire ↗